Description
Andarin 26 mg Onatrio pharam — andarine (S-4) from Onatrio pharam at 26 mg. Non-steroidal partial AR agonist. Tissue-selective for muscle and bone. Characteristic side-effect: yellow vision tint at higher doses (reversible).
Key Benefits
- S-4 SARM — selective androgen receptor activation with partial profile
- Effective at body-recomposition dosing
- Distinct visual side-effect (yellow tinge) from ocular-pigment binding
- Oral once or twice daily
- Mild HPTA suppression — mini-PCT advisable
- Each unit dosed at 26 mg — see Recommended Dosage below for protocol-specific intake
How It Works
Selective androgen receptor modulator with partial agonism profile. Tissue-selective effect on muscle and bone with minimal prostate/skin impact. Downstream anabolic signal milder than full-potency SARMs (ligandrol, RAD-140).
Pharmacokinetics
Plasma half-life approximately 4 hours — twice-daily dosing required. Oral bioavailability reasonable. Reconstituted oil or powder stable at room temperature.
Potential Side Effects
Signature visual disturbance: yellowing tint to vision, especially in low light. Resolves within 1–2 weeks of discontinuation. Mild HPTA suppression. HDL drops slightly.
Cycle & Stacking Guide
6–8 week cycles, 25–50 mg/day. Mini-PCT (Nolva 20 mg × 3 weeks) after 8-week runs. Often stacked with Ostarine or cardarine for cutting protocols.
Manufacturer Notes
Onatrio pharam is an independent producer in the research-compound market. Before first use, request the batch-specific Certificate of Analysis and confirm the vial’s tamper-evident seal is intact.
Storage & Handling
Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.
Reviews
There are no reviews yet.